Autocrine/paracrine sphingosine-1-phosphate fuels proliferative and stemness qualities of glioblastoma stem cells

GLIA

Volumn 62, Issue 12, 2014, Pages 1968-1981

  Marfia, Giovanni ^a   Campanella, Rolando ^b   Navone, Stefania Elena ^a   Di Vito, Clara ^a   Riccitelli, Elena ^a   Hadi, Loubna Abdel ^a   Bornati, Andrea ^b   de Rezende, Gisele ^b   Giussani, Paola ^a   Tringali, Cristina ^a   Viani, Paola ^a   Rampini, Paolo ^a   Alessandri, Giulio ^c   Parati, Eugenio ^c   Riboni, Laura ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

CD133; Ceramide; Growth factors; Sphingolipid metabolism; Stem cell niche

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CD133 ANTIGEN; CD15 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; THY 1 ANTIGEN; VASCULOTROPIN; CERAMIDE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; KI 67 ANTIGEN; LYSOPHOSPHOLIPID; PROPANEDIOL DERIVATIVE; SPHINGOLIPID; SPHINGOSINE 1-PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER STEM CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN TUMOR; CELL CULTURE; DRUG EFFECTS; DRUG SCREENING; EXTRACELLULAR FLUID; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL CULTURE;

ANIMALS; BRAIN NEOPLASMS; CELL PROLIFERATION; CELLS, CULTURED; CERAMIDES; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR FLUID; FIBROBLAST GROWTH FACTOR 2; GLIOBLASTOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KI-67 ANTIGEN; LYSOPHOSPHOLIPIDS; MICE; MICE, SCID; MIDDLE AGED; NEOPLASTIC STEM CELLS; PROPYLENE GLYCOLS; SPHINGOLIPIDS; SPHINGOSINE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930040640     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22718     Document Type: Article

References (58)

1. Abuhusain HJ, Matin A, Qiao Q, Shen H, Kain N, Day BW, Stringer BW, Daniels B, Laaksonen MA, Teo C, McDonald KL, Don AS. 2013. A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis. J Biol Chem 288:37355-37364.
2. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. 2004. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14:43-47.
3. Anelli V, Bassi R, Tettamanti G, Viani P, Riboni L. 2005. Extracellular release of newly synthesized sphingosine-1-phosphate by cerebellar granule cells and astrocytes. J Neurochem 92:1204-1215.
4. Annabi B, Lachambre MP, Plouffe K, Sartelet H, Béliveau R. 2009. Modulation of invasive properties of CD133+ glioblastoma stem cells: Arole for MT1-MMP in bioactive lysophospholipid signaling. Mol Carcinog 48:910-919.
5. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760.
6. Bassi R, Anelli V, Giussani P, Tettamanti G, Viani P, Riboni L. 2006. Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors. Glia 53:621-630.
7. Cavalli AL, Ligutti JA, Gellings NM, Castro E, Page MT, Klepper RE, Palade PT, McNutt WT, Sabbadini RA. 2002. The Role of TNFα and sphingolipid signaling in cardiac hypoxia: Evidence that cardiomyocytes release TNFα and sphingosine. Basic Appl Myol 12:167-175.
8. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. 2012. The brain tumor microenvironment. Glia 60:502-514.
9. + niches and single cells in glioblastoma have different phenotypes. Neuro Oncol 104:129-143.
10. Estrada-Bernal A, Palanichamy K, Ray Chaudhury A, Van Brocklyn JR. 2012. Induction of brain tumor stem cell apoptosis by FTY720: A potential therapeutic agent for glioblastoma. Neuro Oncol 14:405-415.
11. Filatova A, Acker T, Garvalov BK. 2013. The cancer stem cell niche(s): The crosstalk between glioma stem cells and their microenvironment. Biochim Biophys Acta 1830:2496-2508.
12. Furuya H, Shimizu Y, Kawamori T. 2011. Sphingolipids in cancer. Cancer Metastasis Rev 30:567-576.
13. Hadjipanayis CG, Van Meir EG. 2009. Brain cancer propagating cells: Biology, genetics and targeted therapies. Trends Mol Med 15:519-530.
14. He J, Liu Y, Zhu T, Zhu J, DiMeco F, Vescovi AL, Heth JA, Muraszko KM, Fan X, Lubman DM. 2012. CD90 is identified as a marker for cancer stem cells in primary high grade gliomas using tissue microarrays. Mol Cell Proteomics 11:1-8.
15. Heddleston JM, Hitomi M, Venere M, Flavahan WA, Yan K, Kim Y, Minhas S, Rich JN, Hjelmeland AB. 2011. Glioma stem cell maintenance: The role of the microenvironment. Curr Pharm Des 17:2386-2401.
16. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. 2002. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39:193-206.
17. Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, Zipkin RE, Dent P, Kordula T, Milstien S, Spiegel S. 2009. Targeting sphingosine kinase 1 inhibits AKT signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 69:6915-6923.
18. Kimura A, Ohmori T, Ohkawa R, Madoiwa S, Mimuro J, Murakami T, Kobayashi CE, Hoshino CY, Yatomi AY, Sakata DY. 2007. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 25:115-124.
19. Krishnamoorthy S, Honn KV. 2011. Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment. Cancer Metastasis Rev 30:613-618.
20. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R. 2001. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 95:190-198.
21. Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S, Kornblum HI. 2009. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells 27:980-987.
22. Lathia JD, Heddleston JM, Venere M, Rich JN. 2011a. Deadly teamwork: Neural cancer stem cells and the tumor microenvironment. Cell Stem Cell 8:482-485.
23. Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, Liu L, Eyler CE, Heddleston JM, Wu Q, Minhas S, Soeda A, Hoeppner DJ, Ravin R, McKay RD, McLendon RE, Corbeil D, Chenn A, Hjelmeland AB, Park DM, Rich JN. 2011b. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis 2:e200.
24. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA. 2006. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391-403.
25. Le Stunff H, Milstien S, Spiegel S. 2004. Generation and metabolism of bioactive sphingosine-1-phosphate. J Cell Biochem 92:882-899.
26. Li G, Chen Z, Hu YD, Wei H, Li D, Ji H, Wang DL. 2009. Autocrine factors sustain glioblastoma stem cell self-renewal. Oncol Rep 21:419-424.
27. Liu X, Zhang QH, Yi GH. 2012. Regulation of metabolism and transport of sphingosine-1-phosphate in mammalian cells. Mol Cell Biochem 363:21-33.
28. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. 2007. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109.
29. Maceyka M, Harikumar KB, Milstien, S, Spiegel S. 2012. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 22:50-60.
30. Mora R, Dokic I, Kees T, Hüber CM, Keitel D, Geibig R, Brügge B, Zentgraf H, Brady NR, Régnier-Vigouroux A. 2010. Sphingolipid rheostat alterations related to transformation can be exploited for specific induction of lysosomal cell death in murine and human glioma. Glia 58:1364-1383.
31. Oliver TG, Wechsler-Reya RJ. 2004. Getting at the root and stem of brain tumors. Neuron 42:885-888.
32. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, Lin CY, Hla T. 2007. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282:9082-9089.
33. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, De Maria R. 2008. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 14:8205-8212.
34. Persano L, Rampazzo E, Basso G, Viola G. 2013. Glioblastoma cancer stem cells: Role of the microenvironment and therapeutic targeting. Biochem Pharmacol 85:612-622.
35. Pettus BJ, Chalfant CE, Hannun YA. 2002. Ceramide in apoptosis: An overview and current perspectives. Biochim Biophys Acta 1585:114-125.
36. Piccirillo SG, Combi R, Cajola L, Patrizi A, Redaelli S, Bentivegna A, Baronchelli S, Maira G, Pollo B, Mangiola A, DiMeco F, Dalprà L, Vescovi AL. 2009. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene 28:1807-1811.
37. Pojo M, Costa BM. 2011. Molecular hallmarks of gliomas. In: Garami M, editor. Molecular targets of CNS tumors. Rijeka: InTech. pp 177-200.
38. Pyne NJ, Pyne S. 2010. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 10:489-503.
39. Ralte AM, Sharma MC, Karak AK, Mehta VS, Sarkar C. 2001. Clinicopathological features, MIB-1 labelling index and apoptotic index in recurrent astrocytic tumors. Pathol Oncol Res 7:267-278.
40. Riboni L, Campanella R, Bassi R, Villani R, Gaini SM, Martinelli-Boneschi F, Viani P, Tettamanti G. 2002. Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 39:105-113.
41. Riboni L, Viani P, Tettamanti G. 2000. Estimating sphingolipid metabolism and trafficking in cultured cells using radiolabeled compounds. Methods Enzymol 311:656-682.
42. Riccitelli E, Giussani P, Di Vito C, Condomitti G, Tringali C, Caroli M, Galli R, Viani P, Riboni L. 2013. Extracellular sphingosine-1-phosphate: A novel actor in human glioblastoma stem cell survival. PLoS ONE 8:e68229.
43. Rosen H, Goetzl EJ. 2005. Sphingosine-1-phosphate and its receptors: An autocrine and paracrine network. Nat Rev Immunol 5:560-570.
44. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. 2009. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 78:743-768.
45. Salmaggi A, Boiardi A, Gelati M, Russo A, Calatozzolo C, Ciusani E, Sciacca FL, Ottolina A, Parati EA, La Porta C, Alessandri G, Marras C, Croci D, De Rossi M. 2006. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 54:850-860.
46. Schmidt KF, Ziu M, Schmidt NO, Vaghasia P, Cargioli TG, Doshi S, Albert MS, Black PM, Carroll RS, Sun Y. 2004. Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas. J Neurooncol 68:207-215.
47. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. 2006. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2:494-503.
48. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schänzer A, Meletis K, Wolter M, Sommerlad D, Henze AT, Nistér M, Reifenberger G, Lundeberg J, Frisén J, Acker T. 2010. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2a. Brain 133:983-995.
49. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. 2004. Identification of human brain tumour initiating cells. Nature 432:396-401.
50. Soeda A, Inagaki A, Oka N, Ikegame Y, Aoki H, Yoshimura S, Nakashima S, Kunisada T, Iwama T. 2008. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J Biol Chem 283:10958-1866.
51. Spiegel S, Merrill AH Jr. 1996. Sphingolipid metabolism and cell growth regulation. FASEB J 10:1388-1397.
52. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996.
53. Takuwa Y, Okamoto Y, Yoshioka K, Takuwa N. 2012. Sphingosine-1-phosphate signaling in physiology and diseases. Biofactors 38:329-337.
54. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. 2005. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: Roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 64:695-705.
55. Van Brocklyn J, Letterle C, Snyder P, Prior T. 2002. Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: Role of ERK/MAP kinase and phosphatidylinositol 3-kinase β. Cancer Lett 181:195-204.
56. Yester JW, Tizazu E, Harikumar KB, Kordula T. 2011. Extracellular and intracellular sphingosine-1-phosphate in cancer. Cancer Metastasis Rev 30:577-597.
57. Yoshida Y, Nakada M, Harada T, Tanaka S, Furuta T, Hayashi Y, Kita D, Uchiyama N, Hayashi Y, Hamada J. 2010. The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labelling index and predicts survival of glioblastoma patients. J Neuro Oncol 9:41-47.
58. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC. 2008. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14:123-129.